Brief: Xvivo Perfusion Q3 EBITDA Swings To Loss Of SEK 11.2 Million
Oct 23 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* Q3 NET SALES OF NON-DURABLE GOODS SEK 42.3 MILLION VERSUS
SEK
50.1 MILLION YEAR AGO
* COVID-19 PANDEMIC CONTINUED TO HAVE AN IMPACT ON SALES
DURING
Q3, BUT TO A LOWER EXTENT THAN IN Q2.
* Q3 EBITDA LOSS SEK 11.2 MILLION VERSUS PROFIT SEK 9.0
MILLION
YEAR AGO
Source text for Eikon: ID:
Further company coverage: XVIVO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength